Kyverna Therapeutics, Inc.
KYTX
$7.18
$0.629.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 137.19M | 135.93M | 127.43M | 112.47M | 96.15M |
| Gross Profit | -137.19M | -135.93M | -127.43M | -112.47M | -96.15M |
| SG&A Expenses | 37.20M | 38.50M | 36.02M | 31.83M | 25.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 174.39M | 174.43M | 163.45M | 144.30M | 121.84M |
| Operating Income | -174.39M | -174.43M | -163.45M | -144.30M | -121.84M |
| Income Before Tax | -160.99M | -158.70M | -145.42M | -127.48M | -110.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -160.99 | -158.70 | -145.42 | -127.48 | -110.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -160.99M | -158.70M | -145.42M | -127.48M | -110.66M |
| EBIT | -174.39M | -174.43M | -163.45M | -144.30M | -121.84M |
| EBITDA | -173.26M | -173.24M | -162.25M | -143.12M | -120.75M |
| EPS Basic | -3.72 | -3.67 | -3.37 | -3.46 | -28.53 |
| Normalized Basic EPS | -2.37 | -2.34 | -2.14 | -2.17 | -17.81 |
| EPS Diluted | -3.72 | -3.67 | -3.37 | -3.46 | -28.53 |
| Normalized Diluted EPS | -2.37 | -2.34 | -2.14 | -2.17 | -17.81 |
| Average Basic Shares Outstanding | 173.09M | 172.83M | 172.73M | 153.27M | 110.83M |
| Average Diluted Shares Outstanding | 173.09M | 172.83M | 172.73M | 153.27M | 110.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |